STOCK TITAN
  1. Home
  2. Sec-filings
  3. SCYX
  4. [8-K] SCYNEXIS INC Reports Material Event

Director Steven Gilman to retire from SCYNEXIS (NASDAQ: SCYX) Board

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

SCYNEXIS, Inc. reported that board member Steven C. Gilman plans to retire from the Board and will not stand for reelection at the company’s 2026 annual meeting of stockholders. His term will end at that meeting, when his current directorship expires.

Until the 2026 annual meeting, Dr. Gilman will continue to serve as Chair of the Compensation Committee and as a member of the Nominating and Corporate Governance Committee. The company stated that his decision was not due to any disagreement regarding its operations, policies, practices, strategy, management, or Board.

Positive

  • None.

Negative

  • None.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Notice date April 16, 2026 Date Dr. Gilman notified SCYNEXIS of his intent to retire
End of term 2026 annual meeting When Dr. Gilman’s Board term and service will conclude
Common stock par value $0.001 per share Par value of SCYNEXIS common stock listed on Nasdaq Capital Market
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Compensation Committee financial
"Chair of the Compensation Committee and a member"
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
Nominating and Corporate Governance Committee regulatory
"and a member of the Nominating and Corporate Governance Committee"
A nominating and corporate governance committee is a group within a company's board of directors responsible for selecting and recommending individuals to serve as company leaders, such as directors or executives. They also develop and oversee policies to ensure the company is run fairly, ethically, and transparently. This committee matters to investors because it helps ensure the company is well-managed and guided by qualified, responsible leadership.
annual meeting of stockholders regulatory
"not stand for reelection at the Company’s 2026 annual meeting of stockholders"
Understanding 8-K Material Events →
false0001178253SCYNEXIS INC00011782532026-04-162026-04-16

 

UNITED STATES


SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 16, 2026

SCYNEXIS, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-36365

56-2181648

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

1 Evertrust Plaza

13th Floor

Jersey City, New Jersey

07302-6548

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 201 884-5485

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

Trading
Symbol(s)


Name of each exchange on which registered

Common Stock, par value $0.001 per share

SCYX

The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

 

On April 16, 2026, Steven C. Gilman, a member of the Board of Directors (the “Board”) of SCYNEXIS, Inc. (the “Company”), notified the Company of his intent to retire as a member of the Board and therefore not stand for reelection at the Company’s 2026 annual meeting of stockholders (the “2026 Annual Meeting”). Accordingly, Dr. Gilman’s term as a director will end when his current term expires at the 2026 Annual Meeting. Dr. Gilman will remain in his roles as the Chair of the Compensation Committee and a member of the Nominating and Corporate Governance Committee of the Board until the conclusion of the 2026 Annual Meeting. The Company’s management and the Board thank Dr. Gilman for his years of service and valuable contributions to the Company.

 

Dr. Gilman’s resignation was not the result of any disagreement with the Company on any matter related to the Company’s operations, policies, practices or strategy, the Company’s management or the Board.

 

 

 

 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SCYNEXIS, Inc.

Date:

April 20, 2026

By:

/s/ David Angulo, M.D.

Name:

David Angulo, M.D.
 

Title:

Chief Executive Officer

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What director change did SCYNEXIS (SCYX) disclose in this 8-K?

SCYNEXIS disclosed that director Steven C. Gilman intends to retire and will not stand for reelection at the 2026 annual meeting. His current term will therefore end at that meeting, and he will step down from the Board at that time.

When will Steven C. Gilman leave the SCYNEXIS (SCYX) Board?

Steven C. Gilman will leave the SCYNEXIS Board at the company’s 2026 annual meeting of stockholders, when his current term expires. Until then, he remains an active director and continues in his committee leadership and membership roles.

Why is SCYNEXIS director Steven C. Gilman retiring from the Board?

The filing states that Steven C. Gilman notified SCYNEXIS of his intent to retire as a Board member and not stand for reelection at the 2026 annual meeting. His decision is described as a retirement, not tied to any disclosed dispute or controversy.

What Board roles will Steven C. Gilman hold at SCYNEXIS until the 2026 meeting?

Until the 2026 annual meeting, Dr. Gilman will remain Chair of the Compensation Committee and a member of the Nominating and Corporate Governance Committee. He continues to participate in oversight of executive pay and Board governance during this transition period.

Filing Exhibits & Attachments

1 document

Other Documents